Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas1, Rajarshi Sengupta2, Trevan Locke2, Sayyed Kaleem Zaidi2, Katie M. Campbell1, John M. Carethers3, Elizabeth M. Jaffee4, E. John Wherry5, Jean-Charles Soria6, and Gypsyamber D’Souza7; for the AACR COVID-19 and Cancer Task Force

Summary: Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

At this time of limited supply of the highly effective COVID-19 vaccines, it is important to gather the evidence on the risk of complications and death resultant from a diagnosis of COVID-19 infection in patients with cancer. After reviewing 28 publications, many of which included relevant information on fatality rates of patients with cancer who developed COVID-19 (1–28), we conclude that patients with an active cancer should be considered for priority access to COVID-19 vaccination, along with other particularly vulnerable populations with risk factors for adverse outcomes with COVID-19. This recommendation is consistent with the Advisory Committee on Immunization Practices (ACIP) within the Centers for Disease Control and Prevention (CDC). The ACIP considered multiple groups to recommend for early access to a limited COVID-19 vaccine supply and concluded that patients with cancer are at a higher risk for severe COVID-19 and should be one of the groups considered for early COVID-19 vaccination (29). Given that there are nearly 17 million people living with a history of cancer in the United States alone, it is critical to understand whether these individuals are at a higher risk to contract SARS-CoV-2 and to experience severe outcomes from COVID-19.

1Department of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California. 2American Association for Cancer Research, Philadelphia, Pennsylvania. 3Department of Internal Medicine and Human Genetics and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan. 4Department of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. 5Department of Systems Pharmacology and Translational Therapeutics, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 6Paris Saclay University, Saint-Aubin, France and Drug Development Department, Gustave Roussy, Villejuif, France. 7Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Note: Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).

Corresponding Author: Antoni Ribas, Jonsson Comprehensive Cancer Center at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail: arribas@mednet.ucla.edu

Cancer Discov 2021;11:233–6
doi: 10.1158/2159-8290.CD-20-1817
© 2020 American Association for Cancer Research.
in patients with hematologic malignancies compared with 25% in patients with solid cancers. Additional factors such as differences in older age, advanced COVID-19 disease and hospitalizations, and overall quality of care received can all affect outcomes of COVID-19 in patients with cancer.

Nine studies did not include a control or reference group in their analysis (Supplementary Table S3; refs. 17–25). These studies reported a high CFR among SARS-CoV-2-infected patients with cancer, which seems to be higher when indirectly compared with existing national or global statistics. However, it is difficult to interpret these data in the absence of an appropriate concurrent control cohort from the same hospital or health care system. The remaining three studies were meta-analyses, two of which confirmed that patients with cancer were at increased risk of fatality and severe illness due to COVID-19 when aggregating all of the available series into an overall estimate (Supplementary Table S4; refs. 26–28).

Information is limited on the effects of COVID-19 vaccination in patients with cancer. Among the 43,540 subjects enrolled in the BNT162b2 mRNA COVID-19 vaccine trial, 3.7% were reported to have cancer, with a total of five patients developing COVID-19 at the time of reporting (one in the vaccine arm and four in the placebo arm; ref. 30). Other large COVID-19 vaccine trials with further follow-up will provide useful information on the effectiveness of the vaccines in patients receiving different cancer treatments, as there are currently not enough data to evaluate the interactions between active oncologic therapy with the ability to induce protective immunity to COVID-19 with vaccination (30). Given the evidence that the COVID-19 vaccines may provide greater levels of neutralizing antibodies than SARS-CoV2 infection in a substantial number of patients (31, 32), it would be of high importance to offer priority vaccinations to patients receiving cytotoxic chemotherapy, in particular for hematologic malignancies. Current data suggest that patients with hematologic malignancies have limited immune responses to COVID-19 (33). Patients who do not mount a strong immune response against SARS-CoV2 are likely to shed the virus for a longer time and be a source of continued unintended exposure infecting other persons. Therefore, the case for vaccinating patients with certain cancers who have limited ability to mount a natural neutralizing antibody response to COVID-19 infection is further strengthened to prevent spread to others, in particular given their need for frequent visits to clinics to continue with their cancer care. It is possible that patients with certain cancers receiving anti-CD20 or cytotoxic therapies may not demonstrate an antibody response to the COVID-19 vaccination, but because the current vaccines demonstrate a strong T-cell response, it is possible that they would still result in protective T-cell immunity. Therefore, the benefit of COVID-19 vaccination may not be adequately assessed with serologic testing in these patients.

Finally, after more than a decade of clinical testing, there is currently no evidence that cancer immunotherapy with immune-checkpoint blockade increases the complications from any prior viral vaccine administration. Despite that three of the series we reviewed (5, 19, 21) reported that patients receiving cancer immunotherapies had increased risk of complications and death from COVID-19, it is now recognized that this may reflect the confluence of comorbidities and risk factors in these patients; for example, patients with lung cancer induced by cigarette smoke, who are more likely to have preexisting lung inflammatory disease, which is an adverse risk factor for COVID-19, are more likely to be treated with immune-checkpoint blockade therapies (34). This patient population reflecting several comorbidities may be particularly vulnerable and would benefit from priority vaccination. Therefore, it is reasonable to recommend that patients receiving cancer immunotherapies should be considered for priority COVID-19 vaccination regardless of receiving this therapy. We conclude that the data in these studies support the recommendation to provide priority COVID-19 vaccination to patients with cancer due to their increased risk of mortality.

Figure 1. Scatter plot of COVID-19–related CFRs from series comparing rates from patients with cancer (red dots) with patients without cancer (gray dots). [Series includes publications from Sng et al. (2); Cattaneo et al. (7); Meng et al. (9); Mehta et al. (11); Brar et al. (6); Ruthrich et al. (4); Lunski et al. (5); Tian et al. (10); Wang et al. (3); and Dai et al. (12)].

COVID-19 case fatality rate in patients with or without cancer

<table>
<thead>
<tr>
<th>Series</th>
<th>n</th>
<th>CFR (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sng et al. (2)</td>
<td>320</td>
<td>12.5</td>
<td>0.02</td>
</tr>
<tr>
<td>Cattaneo et al. (7)</td>
<td>204</td>
<td>13.3</td>
<td>0.02</td>
</tr>
<tr>
<td>Meng et al. (9)</td>
<td>2,865</td>
<td>10.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mehta et al. (11)</td>
<td>1,306</td>
<td>15.3</td>
<td>0.894</td>
</tr>
<tr>
<td>Brar et al. (6)</td>
<td>585</td>
<td>10.3</td>
<td>0.9</td>
</tr>
<tr>
<td>Ruthrich et al. (4)</td>
<td>3,071</td>
<td>15.5</td>
<td>0.004</td>
</tr>
<tr>
<td>Lunski et al. (5)</td>
<td>5,145</td>
<td>10.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tian et al. (10)</td>
<td>17,130</td>
<td>10.0</td>
<td>0.001</td>
</tr>
<tr>
<td>Wang et al. (3)</td>
<td>16,570</td>
<td>9.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Wang et al. (3)</td>
<td>641</td>
<td>9.7</td>
<td>0.05</td>
</tr>
<tr>
<td>Dai et al. (12)</td>
<td>1,308</td>
<td>10.0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
with COVID-19 infection. This recommendation should result in early vaccination to patients who are currently receiving treatment for cancer, or have an advanced cancer that may result in increased risk of complications from COVID-19, in particular for patients with hematologic malignancies and lung cancer. It is unclear whether this recommendation should be applicable to patients with a past diagnosis of cancer, as cancer survivors can be considered to have the same risk as other persons with matched age and other risk factors. The fact that patients undergoing cancer treatments are in very frequent contact with health care workers increases the risk of exposure and puts the patients at the front line of our health care system.

Authors’ Disclosures

A. Ribas reports personal fees from Amgen (honoraria), Chugai (honoraria), Genentech (honoraria), Merck (honoraria), Novartis (honoraria), Roche (honoraria), Sanofi (honoraria), Vedanta (honoraria), Advaxis (scientific advisory board member, honoraria, stock), Arixo (scientific advisory board member, honoraria, stock), Arcus (scientific advisory board member, honoraria, stock), Compugen (scientific advisory board member, honoraria, stock), Aprez (scientific advisory board member, honoraria, stock), CytomX (scientific advisory board member, honoraria, stock), Five Prime (scientific advisory board member, honoraria, stock), Highlight (scientific advisory board member, honoraria, stock), ImaginAb (scientific advisory board member, honoraria, stock), Isoplexus (scientific advisory board member, honoraria, stock), Kite/Gilead (scientific advisory board member, honoraria, stock), Lutris (scientific advisory board member, honoraria, stock), Merus (scientific advisory board member, honoraria, stock), PACT (scientific advisory board member, honoraria, stock), RAPT (scientific advisory board member, honoraria, stock), RgenX (scientific advisory board member, honoraria, stock), and Tango Therapeutics (scientific advisory board member, honoraria, stock) and grants from NCI, Agilent, Bristol-Myers Squibb through Stand Up To Cancer (SU2C), the Melanoma Research Alliance, and the Parker Institute for Cancer Immunotherapy outside the submitted work. R. Sengupta, T. Locke, and S.K. Zaidi are employed by the American Association for Cancer Research. E.M. Jaffee reports grants from Bristol-Myers Squibb; personal fees from Genocea (consultation), Achilles (consultation), Dragonfly (consultation), and CSTONE (consultation); other from AbMeta (founder) and PICI (consultant); and reports grants from and is the Chief Medical Advisor for Lustgarten Foundation outside the submitted work. No disclosures were reported by the other authors.

Published first December 19, 2020.

REFERENCES


Figure 2. Forest plot of series reporting hazard ratios (HR; top in red) or odds ratios (OR; bottom in blue) for death, or severity of COVID-19 in the case of the Tian series, in patients with COVID-19 and cancer compared with no cancer. The size of the symbol is proportional to the number of individuals in each series. The line represents the lower and upper limits of the 95% confidence intervals. Negative HR or OR values favor decreased risk for death, whereas positive values represent increased risk for death or severity of COVID-19. [Series includes publications from Meng et al. (9); Williamson et al. (8); Mehta et al. (11); Williamson et al. (8); Sng et al. (2); Brar et al. (6); Tian et al. (10); Dai et al. (12); and Lunski et al. (5)].


Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas, Rajarshi Sengupta, Trevan Locke, et al.


**Updated version**
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-20-1817

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2020/12/19/2159-8290.CD-20-1817.DC1

**Cited articles**
This article cites 26 articles, 7 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/11/2/233.full#ref-list-1

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, use this link
http://cancerdiscovery.aacrjournals.org/content/11/2/233.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.